Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Fig. 2

Trial profile. a In cycle 1, 106 patients received pertuzumab, 104 patients received trastuzumab, and 103 patients received vinorelbine. b The 15 patients ongoing with any study treatment at time of study closure are also counted under administrative/other reasons

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us